(NASDAQ: ABUS) Arbutus Biopharma's forecast annual revenue growth rate of 12.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Arbutus Biopharma's revenue in 2025 is $6,171,000.On average, 3 Wall Street analysts forecast ABUS's revenue for 2025 to be $1,367,742,983, with the lowest ABUS revenue forecast at $1,206,325,184, and the highest ABUS revenue forecast at $1,608,433,579. On average, 1 Wall Street analysts forecast ABUS's revenue for 2026 to be $1,537,585,910, with the lowest ABUS revenue forecast at $1,537,585,910, and the highest ABUS revenue forecast at $1,537,585,910.
In 2027, ABUS is forecast to generate $1,690,770,060 in revenue, with the lowest revenue forecast at $1,690,770,060 and the highest revenue forecast at $1,690,770,060.